Story

Eli Lilly Named Top Pharma Pick by Jefferies on Strong Earnings, Raised Outlook

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20262 min read
Eli Lilly Named Top Pharma Pick by Jefferies on Strong Earnings, Raised Outlook
Text size
Background

Jefferies has identified Eli Lilly and Co. (LLY) as its top pick in the large-cap pharmaceutical sector, raising its price target on the stock to $1,440 per share. The updated target, representing an approximate 29% upside from its current price, follows a robust second-quarter performance and increased financial guidance from the drugmaker.

Analyst Boosts Outlook on Earnings Beat

In a recent note, Jefferies analyst Akash Tewari reiterated a Buy rating on Eli Lilly, attributing the optimism to a significant outperformance in the second quarter. The company reported total revenues of approximately $23 billion, easily surpassing consensus estimates of $20.7 billion. Earnings per share (EPS) came in at $8.38, well ahead of the anticipated $6.68.

This strong financial performance was underpinned by surging demand for its key products, prompting the firm to raise its outlook. The analyst's new price target reflects confidence in the company's continued growth trajectory.

Mounjaro and Zepbound Drive Growth

The sales momentum was largely driven by the company's popular GLP-1 drugs for diabetes and weight management. According to Jefferies, sales for these key products exceeded market expectations:

Sample IUX Markets – In-articleAd
  • Mounjaro: Exceeded estimates by 12%, generating approximately $9.94 billion in total revenue.
  • Zepbound: Beat estimates by 6%, bringing in $4.93 billion in revenue.

Eli Lilly's new oral GLP-1 product, Foundayo (orforglipron), also contributed $98 million in its initial launch quarter. The report highlighted the company's dominant market position, noting it holds approximately 60.9% of the U.S. incretin analog market and 54.9% of the international incretin market.

Upgraded Guidance and Market Expansion

Following the strong quarter, Eli Lilly increased its fiscal year 2026 revenue guidance to a range of $85 billion to $87 billion, up from its previous forecast of $82-85 billion. Jefferies views this updated guidance as conservative, with its own model projecting revenues above the high end at $88.5 billion.

Market access continues to expand, with the Medicare Bridge Program potentially adding 20 million eligible patients in the U.S. since its July 1 start. Furthermore, Foundayo recently received approval in the United Kingdom for both weight management and type 2 diabetes. Other investment firms, including Wells Fargo and BMO Capital, have also raised their price targets on Eli Lilly following the results.

Read next

More on Stocks
Back to latest news

LATEST